Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose

Status Completed

Clinical Trial Summary

This study will prospectively collect patients undergoing the standard CROSS regimen in the neoadjuvant setting of the treatment for gastro-oesophageal cancer. The investigators will focus on the potential geometric differences between the OAR and target volume on the initial planning CT and on the kilovolt (kV) cone-beam computed tomography (CBCT). They expect a potential difference in the abdominal part of the planned target volume (PTV) and/or gastro-oesophageal junction part. Furthermore, the impact of gastric filling , potential tumor regression and the accuracy of 5 mm PTV margin in the thoracic PTV will be monitored.

Clinical Trial Description

Optimal radiotherapy planning and delivery is essential for irradiation of gastro-oesophageal junction tumors. There is a need for individualized radiotherapy delivery to the upper abdomen, because of mobility. Likewise, controlling gastric filling by instructing patients about fluid and food intake before treatment, may contribute to positional reproducibility. There is evidence that missing microscopic disease in treating the clinical target volume (CTV) results in a worse prognostic outcome. The investigators want to evaluate wether positional difference of stomach, with and without fasting prescription, has an impact of the delivered dose. They will focus on the part of the CTV extending in the stomach. The investigators hypothesize that measurement of the dose using verification kilovoltage cone beam CTs will provide information on potential cold/hot spots of dose delivery and monitor potential geometric differences during treatment. This may result in a suboptimal treatment and a reconsideration of matching target volume on soft tissue instead of bony landmarks. The investigators will evaluate the first clinical results with DGRT in patients with esophageal cancer. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Adenocarcinoma

Clinical Trial Details

NCT number	NCT02130011
Study type	Interventional
Source	Maastricht Radiation Oncology
Contact
Status	Completed
Phase	N/A
Start date	March 2014
Completion date	September 2015

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05678218` - Preoperative Evaluation of Lymph Nodes of Cholangiocarcinoma
Recruiting	`NCT05161572` - Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer	Phase 2
Recruiting	`NCT02292641` - Beyond TME Origins	N/A
Withdrawn	`NCT05325164` - Methadone for 'Adenocarcinopathic' Pain Treatment	Phase 3
Completed	`NCT02926768` - Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors	Phase 1
Recruiting	`NCT02125240` - Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma	Phase 3
Completed	`NCT02374411` - Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients	N/A
Completed	`NCT02454647` - Induction Chemotherapy, Chemoradiotherapy and Surgery in Locally Advanced Gastric Cancer Patients	N/A
Completed	`NCT01579721` - Prospective Randomized Study of SILS Versus CLS for Rectal Cancer	Phase 4
Completed	`NCT01206530` - FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer	Phase 1/Phase 2
Withdrawn	`NCT01148082` - School Response to Families Who Have Children With Cancer	N/A
Completed	`NCT00548548` - A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer	Phase 3
Completed	`NCT00377936` - EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas	Phase 2
Completed	`NCT00129844` - Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer	Phase 2
Completed	`NCT00183859` - Clinical and Pharmacokinetic Trial of Intra-Abdominal Irinotecan	Phase 1
Recruiting	`NCT01930864` - Metformin Plus Irinotecan for Refractory Colorectal Cancer	Phase 2
Completed	`NCT02498860` - Efficacy and Safety of Adjuvant Pemetrexed Plus Cisplatin for Adenocarcinoma of Lung	Phase 2
Terminated	`NCT01441128` - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer	Phase 1
Active, not recruiting	`NCT04400474` - Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study	Phase 2
Recruiting	`NCT02133196` - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Dose-Guided Radiotherapy in Oesophageal Cancer: Managing the Real Dose — DGRT

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms